Categorized | Stock Profiles

PMCB (PharmaCyte Biotech, Inc.)


Share Button

pmcbPharmaCyte Biotech Inc. (PMCB) is a clinical stage biotechnology company, previously known as Nuvilex, who holds exclusive, global rights for utilization of live cell encapsulation technology, also known as Cell0-in-a-box, for the development and preparation to market of treatments targeting cancers, specifically pancreatic cancer, diabetes, and other diseases.

After a Recent Name Change and Ticker Change to better reflect the medical advancements the company has made, PMCB is nearing its mission to tackle the rising pancreatic cancer rates and has recently received Orphan Drug Designation by the U.S. Food and Drug Administration. Orphan drug designation is a U.S. approval for drugs or treatments for “rare” life threatening diseases.  In 2014, approximately 46,420 new cases of pancreatic cancer were found in the U.S. while nearly 39,590 died of the cancer. Even with the best available chemotherapy, U.S. patients with advanced pancreatic cancer are destined to live, on average, less than one year and the five-year survival rate is less than 7%. PMCB intends to tackle the rates using its unique platform that utilizes Cell-in-a-box live cell encapsulation technology along with low doses of the anticancer prodrug. ifosfamide, to combat advanced, inoperable pancreatic cancer by converting the ifosfamide into an active or “cancer-killing” form. After previous effective clinical trials and another successful trial at the company’s Partner Facility, Austrianova, the company is proceeding with its development preparation and will soon enter Phase 2b clinical trial to improve the quality of life for patients with advanced cancerous tumors.

Moreover, PMCB’s New Subsidiary, Viridis Biotech Inc., will soon present a New Method of Targeted Chemotherapy by combining its exclusive cell encapsulation technology with Cannabinoids or cannabinoid-like compounds for development of treatments for other diseases and medical conditions including pancreatic, brain, and breast cancer. The company will examine and analyze the ways, in collaboration with the University of Northern Colorado, in which the anticancer effectiveness of cannabinoids can reach its highest point while minimizing or eliminating the debilitating side effects usually associated with this form of cancer treatment. Current

The company’s development further advances as PMCB additionally intends to utilize its platform to develop treatments for those diagnosed with Type 1 and Type 2 diabetes. The company’s “Diabetes Consortium”, a designated group of key personnel and industry professionals, have already executed contracts with major institutions that will assist and permit the development of a diabetes treatment using the company’s “formula.”

 

Symbol: PMCB  [ Current PPS: $0.1559  Outstanding Shares: 699.3M  Float: 529.2M  – a/o January 20, 2015 ]

pmcb chart

Website(s): www.nuvilex.com

 

 

Market

  • Receiving orphan drug designation brings up to 7 years of market exclusivity in the U.S.
  • There are over 380 million people worldwide who have been diagnosed with diabetes however 185 million people remain undiagnosed.
  • According to an article posted on the Journal of the National Cancer Institute, pancreatic disease is currently the 5th leading cancer-related cause of death in the U.S. and has the potential to rise to the 2nd leading cause by 2030.
  • Even with the best available chemotherapy, U.S. patients with advanced pancreatic cancer are destined to live, on average, less than one year and the five-year survival rate is less than 7%.
  • A professor of gastroenterology and hepatology in Sweden states pancreatic cancer is the world’s greatest oncological challenge due to its late diagnosis and lack of money research treatments.
  • Only 22% of those diagnosed with pancreatic cancer qualify for surgery.
  • Globally, breast cancer is the 5th most common cancer-related cause of death
  • The Breast Cancer market is estimated to total $11 billion by 2018.
  • The cannabinoid market is estimated to total $30-$50 billion however, based on the Federal Medical Cannabis Program internal estimates believe the market will actually be worth $74 billion in 2017.
  • Cannabinoids have been found to aid migraine headaches, insomnia, depression, epileptic seizures, chronic heartburn, AIDS/HIV, Alzheimers, Asthma, AutoimmuneDisease, Cancer, Crohn’s Disease, Diabetes, Digestive Disover, Gastro Intestinal (GERD), Glaucoma, High Blood Pressure, Influenza, Multiple Sclerosis, Pain Management, and Tourette Syndrome.

 

Get Updates on PMCB by Signing Up to our Free E-mail Newsletter!

This post was written by:

- who has written 2169 posts on StockRockandRoll.


Contact the author

Comments are closed.


© 2021 MJ Capital, LLC | All rights reserved